WO2001057233A3 - Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides - Google Patents

Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides Download PDF

Info

Publication number
WO2001057233A3
WO2001057233A3 PCT/US2001/002611 US0102611W WO0157233A3 WO 2001057233 A3 WO2001057233 A3 WO 2001057233A3 US 0102611 W US0102611 W US 0102611W WO 0157233 A3 WO0157233 A3 WO 0157233A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides
polypeptides
pref
methods
materials relating
Prior art date
Application number
PCT/US2001/002611
Other languages
French (fr)
Other versions
WO2001057233A2 (en
Inventor
Chiauyun Kuo
Dana A Haley
Bryan J Boyle
Matthew C Arterburn
Y Tom Tang
Chenghua Liu
Radoje A Drmanac
Original Assignee
Hyseq Inc
Chiauyun Kuo
Dana A Haley
Bryan J Boyle
Matthew C Arterburn
Y Tom Tang
Chenghua Liu
Radoje A Drmanac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyseq Inc, Chiauyun Kuo, Dana A Haley, Bryan J Boyle, Matthew C Arterburn, Y Tom Tang, Chenghua Liu, Radoje A Drmanac filed Critical Hyseq Inc
Priority to AU2001234582A priority Critical patent/AU2001234582A1/en
Priority to CA002398215A priority patent/CA2398215A1/en
Priority to JP2001558045A priority patent/JP2003521928A/en
Priority to EP01906704A priority patent/EP1261736A4/en
Priority to US10/311,824 priority patent/US20040122220A1/en
Publication of WO2001057233A2 publication Critical patent/WO2001057233A2/en
Publication of WO2001057233A3 publication Critical patent/WO2001057233A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted Pref-1-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from adult human brain (Hyseq clone identification numbers 7958079 (SEQ ID NO:1)). Other aspects of the invention include vectors containing processes for producing novel human secreted Pref-1-like polypeptides, and antibodies specific for such polypeptides.
PCT/US2001/002611 2000-01-25 2001-01-25 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides WO2001057233A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001234582A AU2001234582A1 (en) 2000-01-25 2001-01-25 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
CA002398215A CA2398215A1 (en) 2000-01-25 2001-01-25 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
JP2001558045A JP2003521928A (en) 2000-01-25 2001-01-25 Methods and materials for preadipocyte factor-1-like (Pref-1-like) polypeptides and polynucleotides
EP01906704A EP1261736A4 (en) 2000-01-25 2001-01-25 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
US10/311,824 US20040122220A1 (en) 2001-01-25 2001-01-25 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49140400A 2000-01-25 2000-01-25
US09/491,404 2000-01-25
US65100800A 2000-08-29 2000-08-29
US09/651,008 2000-08-29

Publications (2)

Publication Number Publication Date
WO2001057233A2 WO2001057233A2 (en) 2001-08-09
WO2001057233A3 true WO2001057233A3 (en) 2002-03-07

Family

ID=27050422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/002611 WO2001057233A2 (en) 2000-01-25 2001-01-25 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides

Country Status (5)

Country Link
EP (1) EP1261736A4 (en)
JP (1) JP2003521928A (en)
AU (1) AU2001234582A1 (en)
CA (1) CA2398215A1 (en)
WO (1) WO2001057233A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523592A (en) * 2002-12-27 2007-08-23 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Novel preadipocyte factor-1-like polypeptide
BRPI0708363A2 (en) 2006-03-09 2011-05-24 Om Pharma process for the treatment of warm-blooded animals, including humans, suffering from a disease related to inflammatory cytokine overproduction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513662A (en) * 1999-11-09 2003-04-15 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 15 human secretory proteins
JP2004500100A (en) * 2000-03-06 2004-01-08 スミスクライン・ビーチャム・コーポレイション New compound

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENEMBL [online] CARLSSON ET AL.: "Growth hormone and prolactin stimulate the expression of rat poreadipocyte factor-1/delta-like protein in pancreatic islet: molecular cloning and expressin pattern during development and growth of the endocrine pancrease", XP002945245, Database accession no. U25680 *
ENDOCRINOLOGY, vol. 9, 26 November 1997 (1997-11-26), pages 3940 - 3948 *
See also references of EP1261736A4 *
WATSON ET AL.: "Recombinant DNA: A short course", 1983, W.H. FREEMAN AND COMPANY, NEW YORK, XP002945246 *

Also Published As

Publication number Publication date
CA2398215A1 (en) 2001-08-09
WO2001057233A2 (en) 2001-08-09
EP1261736A2 (en) 2002-12-04
AU2001234582A1 (en) 2001-08-14
JP2003521928A (en) 2003-07-22
EP1261736A4 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
WO2001088092A3 (en) Methods and materials relating to stem cell factor-like (scf-like) polypeptides and polynucleotides
WO2001077169A3 (en) Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
WO2001055336A3 (en) Methods and materials relating to cd84-like polypeptides and polynucleotides
EP1308459A3 (en) Full-length cDNA sequences
WO1994001548A3 (en) Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow
WO2001053454A3 (en) Methods and materials relating to g protein-coupled receptor-like polypeptides and polynucleotides
CA2253238A1 (en) Novel agouti-related gene
CA2167693A1 (en) Melanoma-inhibiting protein
EP1574520A3 (en) Methods and materials relating to neuronal guidance molecule-like (NGM-like) polypeptides and polynucleotides
WO2003029405A3 (en) Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
WO2001055335A3 (en) Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides
WO2001053456A3 (en) Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
WO2001057233A3 (en) Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
WO2001053500A8 (en) Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides
WO2001055333A8 (en) Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
WO2001055337A3 (en) Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
WO2001075064A3 (en) Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides
WO2001055332A3 (en) Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
WO1997002730A3 (en) Enamel matrix related polypeptide
WO2001055435A3 (en) Methods and materials relating to hematopoietic cytokine-like polypeptides and polynucleotides
WO2001057175A3 (en) Methods and materials relating to neurotrimin-like polypeptides and polynucleotides
WO2000004041A3 (en) Methods and molecules relating to cd39-like polypeptides
WO2003040326A3 (en) Methods and materials relating to prokineticin-like polypeptides and polynucleotides
WO1999045107A8 (en) Novel calpain and dna encoding the same
WO1997040069A3 (en) Secreted proteins and polynucleotides encoding them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001906704

Country of ref document: EP

Ref document number: 2398215

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 558045

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001234582

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001906704

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10311824

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001906704

Country of ref document: EP